NeuroSense Therapeutics (NRSN) Net Income towards Common Stockholders (2021 - 2024)
NeuroSense Therapeutics' (NRSN) quarterly Net Income towards Common Stockholders came in at -$1.8 million in Q4 2024, up 84.67% year-over-year from -$959004.6 in Q1 2024, and up 15.95% quarter-over-quarter from -$2.1 million in Q3 2024.
Powered by 
Analysis
NeuroSense Therapeutics (NRSN) Net Income towards Common Stockholders (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$1.8 million for Q4 2024.
- In Q4 2024, Net Income towards Common Stockholders rose 84.67% year-over-year to -$1.8 million; the TTM figure through Dec 2024 stood at -$9.9 million (up 31.42% YoY), while the FY2025 annual figure was -$11.1 million, down 8.58% from the prior year.
- Net Income towards Common Stockholders came in at -$1.8 million for Q4 2024 at NeuroSense Therapeutics, up from -$2.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $4.9 million in Q4 2021 to a low of -$11.6 million in Q4 2023.
- Average Net Income towards Common Stockholders over 4 years is -$2.3 million, with a median of -$2.6 million recorded in 2023.
- The largest YoY upside for Net Income towards Common Stockholders was 150.03% in 2023 against a maximum downside of 626.15% in 2023.
- Over 4 years, Net Income towards Common Stockholders stood at $4.9 million in 2021, then plunged by 132.66% to -$1.6 million in 2022, then slumped by 626.15% to -$11.6 million in 2023, then soared by 84.67% to -$1.8 million in 2024.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.8 million in Q4 2024, -$2.1 million in Q3 2024, and -$3.0 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -782.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 472.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -290.61 Mn |
| 10 | NeuroSense Therapeutics | 8.09 Mn | 7.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -1.77 Mn |
| Sep 30, 2024 | -2.11 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Dec 31, 2023 | -11.55 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | -1.76 Mn |
| Mar 31, 2023 | -2.62 Mn |
| Dec 31, 2022 | -1.59 Mn |
| Sep 30, 2022 | -2.97 Mn |
| Jun 30, 2022 | -3.41 Mn |
| Mar 31, 2022 | -2.67 Mn |
| Dec 31, 2021 | 4.87 Mn |
API Access
NeuroSense Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NRSN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "NRSN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NRSN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();